Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
García-García C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, Aura C, Pérez J, Jessen K, Liu Y, Rommel C, Tabernero J, Baselga J, Scaltriti M. García-García C, et al. Among authors: perez j. Clin Cancer Res. 2012 May 1;18(9):2603-12. doi: 10.1158/1078-0432.CCR-11-2750. Epub 2012 Mar 8. Clin Cancer Res. 2012. PMID: 22407832
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.
Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzmán M, Gili M, Rodríguez O, Rodríguez S, Pérez J, Green SR, Mai S, Rosen N, Hudis C, Baselga J. Scaltriti M, et al. Among authors: perez j. Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3761-6. doi: 10.1073/pnas.1014835108. Epub 2011 Feb 14. Proc Natl Acad Sci U S A. 2011. PMID: 21321214 Free PMC article.
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.
Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J. Ibrahim YH, et al. Among authors: perez j. Cancer Discov. 2012 Nov;2(11):1036-47. doi: 10.1158/2159-8290.CD-11-0348. Epub 2012 Aug 22. Cancer Discov. 2012. PMID: 22915752 Free PMC article.
Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer.
Méndez O, Peg V, Salvans C, Pujals M, Fernández Y, Abasolo I, Pérez J, Matres A, Valeri M, Gregori J, Villarreal L, Schwartz S Jr, Ramon Y Cajal S, Tabernero J, Cortés J, Arribas J, Villanueva J. Méndez O, et al. Among authors: perez j. Clin Cancer Res. 2018 Dec 15;24(24):6367-6382. doi: 10.1158/1078-0432.CCR-18-0517. Epub 2018 Aug 22. Clin Cancer Res. 2018. PMID: 30135148
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.
Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, Pérez J, Vidal M, Muñoz-Couselo E, Carreras MJ, Sánchez-Ollé G, Tabernero J, Baselga J, Di Cosimo S. Serrano C, et al. Among authors: perez j. Ann Oncol. 2012 Apr;23(4):897-902. doi: 10.1093/annonc/mdr348. Epub 2011 Aug 9. Ann Oncol. 2012. PMID: 21828361 Free article.
HER2 and hormone receptor-positive breast cancer--blocking the right target.
Cortés J, Saura C, Bellet M, Muñoz-Couselo E, Ramírez-Merino N, Calvo V, Pérez J, Vidal M. Cortés J, et al. Among authors: perez j. Nat Rev Clin Oncol. 2011 May;8(5):307-11. doi: 10.1038/nrclinonc.2010.185. Epub 2010 Dec 14. Nat Rev Clin Oncol. 2011. PMID: 21151204 Review.
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.
Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J. Cortes J, et al. Among authors: perez j. Ann Oncol. 2012 May;23(5):1130-1137. doi: 10.1093/annonc/mdr432. Epub 2011 Oct 4. Ann Oncol. 2012. PMID: 21976387 Free article. Review.
Update on novel therapeutic agents for cervical cancer.
del Campo JM, Prat A, Gil-Moreno A, Pérez J, Parera M. del Campo JM, et al. Among authors: perez j. Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S72-6. doi: 10.1016/j.ygyno.2008.04.016. Epub 2008 Jun 9. Gynecol Oncol. 2008. PMID: 18544460 Review.
5,311 results